RT Journal Article
SR Electronic
T1 Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20092338
DO 10.1101/2020.05.11.20092338
A1 Becker, D.
A1 Sandoval, E.
A1 Amin, A.
A1 De Hoff, P.
A1 Diets, A.
A1 Leonetti, N.
A1 Lim, YW.
A1 Elliott, C.
A1 Laurent, L.
A1 Grzymski, J.
A1 Lu, JT
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20092338.abstract
AB The use of saliva collection for SARS-CoV-2 diagnostics in the ambulatory setting provides several advantages when compared to nasopharyngeal swabs (NPS), including ease of self-collection and reduced use of personal protective equipment (PPE). In addition saliva collection could be advantageous in advising if a convalescent patient is able to return to work after a period of self-quarantine. We investigated the utility of saliva collection in the community setting at Renown Health in a prospective Diagnostic Cohort of 88 patients and in a Convalescent Cohort of 24 patients. In the Diagnostic Cohort, we find that saliva collection has reduced sensitivity (~30% less) relative to NPS. And in our convalescent cohort of patients greater than 8 days and less than 21 days from first symptom, we find that saliva has ~ 50% sensitivity relative to NPS. Our results suggest that rigorous studies in the intended populations should be performed before large-scale screening using saliva as the test matrix is initiated.Competing Interest StatementDB, ES, AA, YWL, JTL are employees of Helix Funding StatementNo external funding was received for this study. Activities were self-funded by the respective institutions.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.